Elutia completes divestiture of orthobiologics business unit for cash proceeds of up to $35 million

- company now focused on proprietary drug-eluting biomatrix platform - silver spring, md., nov. 09, 2023 (globe newswire) -- elutia inc. (nasdaq: elut) (“elutia”), a company pioneering drug-eluting biomatrix products, today announced it completed the divestiture of its orthobiologics business unit to berkeley biologics llc, a wholly owned subsidiary of gni group ltd.
ELUT Ratings Summary
ELUT Quant Ranking